KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer

Neoplasia (United States)

Volumn 16, Issue 3, 2014, Pages 247-256.e2

  Singel, Stina M ^a   Cornelius, Crystal ^a   Zaganjor, Elma ^b   Batten, Kimberly ^a   Sarode, Venetia R ^c   Buckley, Dennis L ^d   Peng, Yan ^c   John, George B ^a   Li, Hsiao C ^a   Sadeghi, Navid ^a   Wright, Woodring E ^a   Lum, Lawrence ^a   Corson, Timothy W ^e   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; KINESIN; KINESIN FAMILY MEMBER 14; PACLITAXEL; PROTEIN KINASE B; UNCLASSIFIED DRUG; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; KIF14 PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL ANCHORAGE; CELL LYSATE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE PROCESSING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING; ADJUVANT THERAPY; CELL PROLIFERATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; PHOSPHORYLATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

BIOMARKERS, TUMOR; BRCA1 PROTEIN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROZYGOTE; HUMANS; KINESIN; NEOADJUVANT THERAPY; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84900453885     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.03.008     Document Type: Article

References (43)

1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, and Pietenpol JA (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767.
2. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, and Haffari G, et al (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399.
3. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, and Mayer I, et al (2013). Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 19, 2723-2733.
4. Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, and Shay JW (2013). A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res 19, 2061-2070.
5. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, and Herschkowitz JI, et al (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci U S A 106, 13820-13825.
6. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, and Perou CM (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12, R68.
7. Hirokawa N, Noda Y, Tanaka Y, and Niwa S (2009). Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 10, 682-696.
8. Verhey KJ and Hammond JW (2009). Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol 10, 765-777.
9. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, and Barr FA (2006). KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 172, 363-372.
10. Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, Marshall CG, Fernandes C, Annis J, and Linsley PS (2006). RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol 26, 3853-3863.
11. Corson TW, Huang A, Tsao MS, and Gallie BL (2005). KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24, 4741-4753.
12. Corson TW and Gallie BL (2006). KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 119, 1088-1094.
13. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, and Gallie BL (2007). KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 13, 3229-3234.
14. Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, and Gallie BL (2012). Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer 130, 1844-1854.
15. Wang Q, Wang L, Li D, Deng J, Zhao Z, He S, Zhang Y, and Tu Y (2013). Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol 37, 79-84.
16. Basavarajappa HD and Corson TW (2012). KIF14 as an oncogene in retinoblastoma: a target for novel therapeutics? Future Med Chem 4, 2149-2152.
17. Ahmed SM, Thériault BL, Uppalapati M, Chiu CW, Gallie BL, Sidhu SS, and Angers S (2012). KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol 199, 951-967.
18. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, Brekken R, Wurz R, Tasker A, and Polverino T, et al (2011). TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 41, 458-470.
19. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, and Partanen A, et al (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15, 907-913.
20. Mao M, Linsley PS, Buser CA, Marshall CG, Kim AS, inventors. Methods for identifying modulators of kinesin activity. Patent WO 2004/109290 A2. 2004.
21. Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, McKerrow JH, and Cohen FE (2002). Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 45, 2695-2707.
22. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, and Ptak J, et al (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
23. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, and Ramakrishna M, et al (2012). The life history of 21 breast cancers. Cell 149, 994-1007.
24. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, and Bignell GR, et al (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404.
25. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, and Yuan Y, et al (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352.
26. Kobayashi H, Ohno S, Sasaki Y, and Matsuura M (2013). Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 30, 1019-1029.
27. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, and Greene MH (2005). Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23, 8629-8635.
28. Schmidt M, Hovelmann S, and Beckers TL (2002). A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br J Cancer 87, 924-932.
29. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, and Fan Z (2003). HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205-3212.
30. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, and Tsichlis PN (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736.
31. Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
32. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, and Menzies A, et al (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39, D945-D950.
33. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, and Hung MC (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3, 245-252.
34. Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, White M, Reichelt J, and Levine B (2012). Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science 338, 956-959.
35. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, and Piccart-Gebhart MJ (2013). Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 39, 935-946.
36. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, and Gonzalez-Angulo AM, et al (2012). Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18, 5816-5828.
37. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, and Deng CX (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3, 389-395.
38. Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, and Penault-Llorca F (2013). Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res 19, 2873-2882.
39. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, and Lee CH (2010). Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer 10, 493.
40. Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, and Longy M, et al (2012). Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72, 5454-5462.
41. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, and Meric- Bernstam F (2004). Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10, 7031-7042.
42. Xu S, Li S, Guo Z, Luo J, Elllis MJ, and Ma CX (2013). Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patientderived xenograft models. Mol Cancer Ther 12, 1665-1675.
43. Firestone AJ, Weinger JS, Maldonado M, Barlan K, Langston LD, O'Donnell M, Gelfand VI, Kapoor TM, and Chen JK (2012). Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature 484, 125-129.